Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review

被引:50
作者
Dandona, Paresh [1 ]
Dhindsa, Sandeep [1 ,2 ]
Ghanim, Husam [1 ]
Saad, Farid [3 ]
机构
[1] SUNY Buffalo, Div Endocrinol Diabet & Metab, Williamsville, NY 14221 USA
[2] St Louis Univ, Div Endocrinol Diabet & Metab, St Louis, MO 63103 USA
[3] Gulf Med Univ, Res Dept, Ajman, U Arab Emirates
关键词
body composition; diabetes complications; insulin resistance; type; 2; diabetes; weight control; HORMONE-BINDING GLOBULIN; ANDROGEN DEPRIVATION THERAPY; TYPE-2; DIABETES-MELLITUS; SKELETAL-MUSCLE; INSULIN-RESISTANCE; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; OLDER MEN; ADIPOSE-TISSUE; DOUBLE-BLIND;
D O I
10.1111/dom.14206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of testosterone in improving sexual symptoms in men with hypogonadism is well known. However, recent studies indicate that testosterone plays an important role in several metabolic functions in males. Multiple PubMed searches were conducted with the use of the terms testosterone, insulin sensitivity, obesity, type 2 diabetes, anaemia, bone density, osteoporosis, fat mass, lean mass and body composition. This narrative review is focused on detailing the mechanisms that underlie the metabolic aspects of testosterone therapy in humans. Testosterone enhances insulin sensitivity in obese men with hypogonadism by decreasing fat mass, increasing lean mass, decreasing free fatty acids and suppressing inflammation. At a cellular level, testosterone increases the expression of insulin receptor beta subunit, insulin receptor substrate-1, protein kinase B and glucose transporter type 4 in adipose tissue and adenosine 5 '-monophosphate-activated protein kinase expression and activity in skeletal muscle. Observational studies show that long-term therapy with testosterone prevents progression from prediabetes to diabetes and improves HbA1c. Testosterone increases skeletal muscle satellite cell activator, fibroblast growth factor-2 and decreases expression of the muscle growth suppressors, myostatin and myogenic regulatory factor 4. Testosterone increases haematocrit by suppressing hepcidin and increasing expression of ferroportin along with that of transferrin receptor and plasma transferrin concentrations. Testosterone also increases serum osteocalcin concentrations, which may account for its anabolic actions on bone. In conclusion, testosterone exerts a series of potent metabolic effects, which include insulin sensitization, maintenance and growth of the skeletal muscle, suppression of adipose tissue growth and maintenance of erythropoiesis and haematocrit.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 100 条
[11]   Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis [J].
Boyle, Peter ;
Koechlin, Alice ;
Bota, Maria ;
d'Onofrio, Alberto ;
Zaridze, David G. ;
Perrin, Paul ;
Fitzpatrick, John ;
Burnett, Arthur L. ;
Boniol, Mathieu .
BJU INTERNATIONAL, 2016, 118 (05) :731-741
[12]   Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure A Double-Blind, Placebo-Controlled, Randomized Study [J].
Caminiti, Giuseppe ;
Volterrani, Maurizio ;
Iellamo, Ferdinando ;
Marazzi, Giuseppe ;
Massaro, Rosalba ;
Miceli, Marco ;
Mammi, Caterina ;
Piepoli, Massimo ;
Fini, Massimo ;
Rosano, Giuseppe M. C. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (10) :919-927
[13]   Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency [J].
Cheetham, T. Craig ;
An, JaeJin ;
Jacobsen, Steven J. ;
Niu, Fang ;
Sidney, Stephen ;
Quesenberry, Charles P. ;
VanDenEeden, Stephen K. .
JAMA INTERNAL MEDICINE, 2017, 177 (04) :491-499
[14]   Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer [J].
Cheung, Ada S. ;
Hoermann, Rudolf ;
Dupuis, Philippe ;
Joon, Daryl Lim ;
Zajac, Jeffrey D. ;
Grossmann, Mathis .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (03) :229-237
[15]   Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial [J].
Coletta, D. K. ;
Sriwijitkamol, A. ;
Wajcberg, E. ;
Tantiwong, P. ;
Li, M. ;
Prentki, M. ;
Madiraju, M. ;
Jenkinson, C. P. ;
Cersosimo, E. ;
Musi, N. ;
DeFronzo, R. A. .
DIABETOLOGIA, 2009, 52 (04) :723-732
[16]   Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis [J].
Corona, Giovanni ;
Maseroli, Elisa ;
Rastrelli, Giulia ;
Isidori, Andrea M. ;
Sforza, Alessandra ;
Mannucci, Edoardo ;
Maggi, Mario .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (10) :1327-1351
[17]   SODIUM-FLUORIDE STIMULATES OSTEOCALCIN IN NORMAL SUBJECTS [J].
DANDONA, P ;
COUMAR, A ;
GILL, DS ;
BELL, J ;
THOMAS, M .
CLINICAL ENDOCRINOLOGY, 1988, 29 (04) :437-441
[18]   AMPK as a Therapeutic Target for Treating Metabolic Diseases [J].
Day, Emily A. ;
Ford, Rebecca J. ;
Steinberg, Gregory R. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2017, 28 (08) :545-560
[19]   Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes [J].
Dhindsa, S ;
Prabhakar, S ;
Sethi, M ;
Bandyopadhyay, A ;
Chaudhuri, A ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (11) :5462-5468
[20]   Hypogonadotropic Hypogonadism in Men With Diabesity [J].
Dhindsa, Sandeep ;
Ghanim, Husam ;
Batra, Manav ;
Dandona, Paresh .
DIABETES CARE, 2018, 41 (07) :1516-1525